Agios Pharmaceuticals vs Xencor
Xencor is the larger business, with $126m of revenue in fiscal 2025 against $54.0m for Agios Pharmaceuticals (2.3 times as much). Agios Pharmaceuticals grew faster (48.0% against 13.7%). Xencor kept more of each dollar of sales as profit: a net margin of -73.2% against -764.0%.
| Latest fiscal year | Agios PharmaceuticalsAGIO, 2025 | XencorXNCR, 2025 |
|---|---|---|
| Revenue | $54.0m | $126m |
| Revenue growth | 48.0% | 13.7% |
| Net income | −$413m | −$91.9m |
| Operating margin | -873.9% | — |
| Net margin | -764.0% | -73.2% |
| Return on equity | -30.2% | -14.0% |
| Free cash flow | −$377m | −$138m |
| Cash | $89.1m | $54.1m |
| Total debt | $0 | $120m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 539 | 260 |
| Market value | $1.87bn | $2.29bn |
| Price vs our value range | — | — |
| Moat score | 32 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 40 sales | 0 buys, 18 sales |